1787 evaluation of transperineal prostatic administration of a PSA-activasted protoxin (PRX302) in men with luts secondary to BPH حسب Elhilali, Mostafa

"…The concentration of PRX302 increased from 0.75 to 10.5mg/ml at a volume of 0.25-1.3 ml/deposit. In the Phase II study, 18 patients were enrolled in 3 cohorts and treated transperineally with a 3 mg/mL fixed concentration of PRX302 and at volumes equivalent to 10%, 20% and 30% of prostate volume. …"
احصل على النص الكامل
احصل على النص الكامل
احصل على النص الكامل
احصل على النص الكامل